Skip to main content
Rare Disease Research

Rare Disease Mouse Models

Since 1998, ingenious targeting laboratory has supported rare disease researchers with custom mouse models for studying disease mechanisms and developing therapeutics. Our rare disease models have contributed to research on lysosomal storage disorders, metabolic diseases, neurodegenerative conditions, and hundreds of other genetic diseases, with results published in peer reviewed journals and supporting therapeutic development for underserved patient populations.

With over 7,000 rare diseases affecting an estimated 300 million people worldwide, mouse models provide essential platforms for developing therapies for conditions that have historically lacked treatment options.

7,000+
Known Rare Diseases
300M
Patients Worldwide
26+
Years Experience
100%
Success Rate

Modeling Rare Genetic Diseases

Patient Mutation Knockins

The most translationally relevant rare disease models express the exact mutations found in patients:

  • Point mutations: Single nucleotide changes causing missense, nonsense, or splice site alterations
  • Small insertions/deletions: Frameshift or in frame modifications
  • Repeat expansions: Trinucleotide or other repeat disorders
  • Regulatory mutations: Changes affecting gene expression
Learn more

Gene Knockout Models

Complete loss of function models represent severe disease alleles:

  • Null alleles: Complete absence of gene product
  • Conditional knockouts: Enable tissue specific or temporal gene deletion
  • Hypomorphic alleles: Reduced but not absent gene function
Learn more

Rare Disease Categories

Lysosomal Storage Disorders

Deficiencies in lysosomal enzymes cause accumulation of substrates:

DiseaseGeneMutation TypesModel Applications
Gaucher diseaseGBA1Point mutations, nullERT, SRT, gene therapy
Fabry diseaseGLAPoint mutations, deletionsERT, chaperone therapy
Pompe diseaseGAAPoint mutations, spliceERT, gene therapy
MPS I (Hurler)IDUAPoint mutations, nullERT, gene therapy
MPS II (Hunter)IDSPoint mutations, deletionsERT, gene therapy
Niemann Pick CNPC1/NPC2Point mutationsSmall molecule, gene therapy

Neuromuscular Diseases

Genetic defects affecting muscle or neuromuscular junction:

DiseaseGeneMutation TypesModel Applications
Duchenne MDDMDDeletions, point mutationsExon skipping, gene therapy
Spinal muscular atrophySMN1/SMN2Deletions, point mutationsASO, gene therapy
ALS (familial)SOD1, C9orf72Point mutations, repeatsSmall molecule, ASO
Charcot Marie ToothPMP22, MFN2Duplications, point mutationsGene therapy

Neurological Rare Diseases

Genetic conditions affecting the nervous system:

DiseaseGeneMutation TypesModel Applications
Huntington diseaseHTTCAG repeat expansionASO, gene silencing
Friedreich ataxiaFXNGAA repeat expansionGene therapy
Rett syndromeMECP2Point mutations, deletionsGene therapy
Angelman syndromeUBE3ADeletions, point mutationsASO, gene therapy

Applications in Therapeutic Development

Gene Therapy Testing

  • •AAV mediated gene replacement efficacy
  • •Dose response and biodistribution studies
  • •Long term expression durability
  • •Safety and immunogenicity assessment

Antisense Oligonucleotide Development

  • •Humanized target sequences for human specific ASOs
  • •Splice modulation efficacy testing
  • •Gene knockdown approaches
  • •Pharmacokinetic and pharmacodynamic studies

Enzyme Replacement Therapy

  • •Efficacy of recombinant enzyme administration
  • •Tissue distribution and uptake
  • •Substrate reduction assessment
  • •Dosing regimen optimization

Small Molecule Development

  • •Pharmacological chaperone efficacy
  • •Substrate reduction therapy
  • •Read through compounds for nonsense mutations
  • •Enzyme activators or stabilizers

Selected Publications

Rare disease models generated by ingenious targeting laboratory:

Chakrabarti S, Klich JD, Khallaf MA, Hulme AJ, Sánchez-Carranza O, Baran Z M, Rossi A, Huang A T-L, Pohl T, Fleischer R, Fürst C, Hammes A, Bégay V, Hörnberg H, Finol-Urdaneta RK, Poole K, Dottori M, Lewin GR. (2024).

Touch sensation requires the mechanically gated ion channel ELKIN1 ↗

Science 6686(383): 992-998

Vacher CM, Lacaille H, O’Reilly JJ, Salzbank J, Bakalar D, Sebaoui S, Liere P, Clarkson-Paredes C, Sasaki T, Sathyanesan A, Kratimenos P, Ellegood J, Lerch JP, Imamura Y, Popratiloff A, Hashimoto-Torii K, Gallo V, Schumacher M, Penn AA. (2021).

Placental endocrine function shapes cerebellar development and social behavior ↗

Nat Neurosci 24(10): 1392-1401

View All Publications

What Researchers Say

“The Hephaestin flox model ingenious has made for us has been great. It has helped generate eight research publications.”

— Joshua Dunaief, PhD, MD

University of Pennsylvania

✦ New for 2026

Breeding Scheme Architect

Plan your single allele breeding strategy, calculate expected genotype ratios, and estimate time to experimental cohorts—all before starting your project.

✓
Visualize breeding paths
✓
Calculate Mendelian ratios automatically
✓
Estimate timeline to study ready cohorts
Try It FreeGet Expert Help

Free Research Tool

No account required

AlleleGene-flox (conditional)
Starting genotypeHeterozygous
TargetHomozygous knockout

→ 3 generations to target genotype

Frequently Asked Questions

Rare disease models include point mutation knockins modeling specific patient variants, knockout models for loss of function diseases, conditional models for tissue specific studies, and humanized models for testing human specific therapeutics. Selection depends on disease mechanism, mutation type, and therapeutic strategy.

Patient mutations are modeled through point mutation knockin, where the exact patient variant is introduced into the mouse gene. Pre germline characterization includes sequence verification to confirm exact mutation incorporation, ensuring mice carry precisely the intended disease allele before mouse generation.

Yes. Rare disease models are extensively used for testing gene therapy approaches including AAV mediated gene replacement, antisense oligonucleotide development, enzyme replacement therapy evaluation, and small molecule therapeutic development. Models enable evaluation of therapeutic efficacy, safety, and long term persistence.

Mouse phenotypes may differ from human disease presentation in severity, age of onset, or specific symptoms. However, models capture core disease mechanisms and enable therapeutic testing. Phenotype validation includes comparison to human disease characteristics and assessment of therapeutic response.

Lab Signals

Rare Disease Research Insights

Expert research insights delivered biweekly. Written by PhD scientists, designed for researchers who need cutting-edge knowledge to advance their projects.

Subscribe Free

Disease Categories

Related Model Types

Therapeutic Applications